Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1

Immunotherapy

Volumn 5, Issue 11, 2013, Pages 1177-1182

  Vassilaros, Stamatis ^a   Tsibanis, Anastasios ^a   Tsikkinis, Annivas ^a   Pietersz, Geoffrey A ^b,c,d   McKenzie, Ian F C ^b   Apostolopoulos, Vasso ^b,c,d,e,f  

^a Prolipsis Breast Diagnostic Center   (Greece)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e VICTORIA UNIVERSITY   (Australia)

^f VA Consulting Services   (Australia)

Author keywords

breast cancer; C type lectin; dendritic cell targeting; immunotherapy; mannan; mannan MUC1; mannose receptor; mannose receptor targeting; MUC1; MUC1 clinical trial; vaccine

Indexed keywords

CANCER VACCINE; MANNAN; MANNOSE RECEPTOR; MUCIN 1; OXIDIZED MANNAN MUC1; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; DENDRITIC CELL; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; LYMPH NODE METASTASIS; MACROPHAGE; MICROMETASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; SKIN METASTASIS; TARGET CELL;

ADENOCARCINOMA; AGED; BREAST NEOPLASMS; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MANNANS; MIDDLE AGED; MUCIN-1; OXIDATION-REDUCTION; SURVIVAL RATE;

EID: 84887222277     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.126     Document Type: Article

References (19)

1. Gendler SJ. MUC1, the rennissance molecule. J. Mammary Gland Biol. Neoplasia 6, 339-353 (2001).
2. Beatson RE, Taylor-Papadimitriou J, Burchell JM. MUC1 immunotherapy. Immunotherapy 2, 305-327 (2012).
3. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy-human clinical studies. Exp. Rev. Vaccines 7, 963-975 (2008).
4. Martinez-Pomares, L. The mannose receptor. J. Leuk. Biol. 92, 1177-1186 (2012).
5. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IFC. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl Acad. Sci. USA 92, 10128-10132 (1995).
6. Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control. Release 161, 25-37 (2012).
7. Steinman RM. Decisions about dendritic cells: past present and future. Annu. Rev. Immunol. 30, 1-22 (2012).
8. Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997). (Pubitemid 28007547)
9. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: infuence of cyclophosphamide and the route of injection. J. Immunother. 24, 172-183 (2001). (Pubitemid 32183063)
10. Loveland BE, Zhao A, White S et al. Mannan-MUC1 pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12, 869-877 (2006). (Pubitemid 43259870)
11. Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8, R27 (2006).
12. Madan RA, Bilusic M, Heery C, Scholm J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin. Oncol. 39, 296-304 (2012).
13. Schimanski CC, Mohler M, Schon M et al. LICC. L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastates: a randomized, placebe-controlled, multicenter, multinational, double-blinded Phase II trial. BMC Cancer 12, 144-150 (2012).
14. Quoix E, Ramlau R, Westeel V, Papai Z et al. Therapeutic vaccination with TG4010 and frst line chemotherapy in advanced non-small cell lung cancer: a controlled Phase 2B trial. Lancet Oncol. 12, 1125-1133 (2011).
15. Rong Y, Qin X, Jin D et al. A Phase I pilot trial of MUC1 peptide pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin. Exp. Med. 12, 173-180 (2012).
16. Ramanathan RK, Lee KM, McKolanis J et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254-264 (2005). (Pubitemid 40174243)
17. Sheng K-C, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118, 372-383 (2006).
18. Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably infuenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18, 574-583 (2000). (Pubitemid 30078538)
19. Oei AL, Moreno M, Verheijen RH et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer 123, 1848-1853 (2008).